VPC
MLTX icon

Vestal Point Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vestal Point Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-550,000
Closed -$26M – 89
2025
Q2 		$26M Buy
550,000
+350,000
+175% +$14.3M 1.37% 24
2025
Q1 		$7.81M Buy
+200,000
New +$8.62M 0.56% 39

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vestal Point Capital's MLTX Position: Q3 2025 in Review

Vestal Point Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 550,000 shares — an estimated $26M sold.

Vestal Point Capital first reported a position in MLTX in Q1 2025 and held it in 2 quarters. The position peaked at $26M in Q2 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Vestal Point Capital reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Vestal Point Capital sold 550,000 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $26M.
  • Vestal Point Capital first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 2 quarters.
  • Vestal Point Capital's MoonLake Immunotherapeutics position peaked at $26M in Q2 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Vestal Point Capital's 13F filing for Q3 2025, filed 14 Nov 2025.